Diabetes Symptom Checklist
Diabetes Symptom Checklist: Patient-Reported Symptom Dimensions · Also known as: DSC-34
The Diabetes Symptom Checklist is a 34-item patient-reported outcome measure assessing the frequency and burden of symptoms directly related to diabetes and its complications. Developed by Grootenhuis and colleagues in 1994, it captures eight symptom dimensions including hyperglycemic symptoms, hypoglycemic symptoms, fatigue, polyuria, neuropathic pain, and psychological distress. The instrument is used to quantify symptom experience and treatment response across diverse diabetes populations.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
The Diabetes Symptom Checklist is used in: (1) Baseline assessment of patients with newly diagnosed diabetes to quantify symptom burden and establish treatment targets; (2) Ongoing monitoring during treatment intensification or change to document symptom response and guide further adjustments; (3) Research investigating prevalence and determinants of specific diabetes symptoms (neuropathic pain, hypoglycemia burden, kidney-related symptoms); (4) Comorbidity assessment distinguishing diabetes-related psychological distress from primary depression or anxiety disorder; (5) Quality of life evaluation in diabetes clinical trials. Appropriate for adults with type 1 or type 2 diabetes; pediatric adaptations available but less commonly used.
Strengths & limitations
- Multidimensional coverage: Eight distinct symptom domains capture the diverse manifestations of diabetes and its complications (acute hyperglycemic, hypoglycemic, chronic complication, and psychological dimensions).
- Patient-centered development: Items derived from qualitative interviews with diabetes patients; reflects real-world symptom experience rather than clinician-assumed burden.
- Responsiveness to treatment: Sensitive to symptom improvement with treatment changes (intensification, technology adoption); subscales show differential sensitivity by intervention type.
- Discrimination between symptom types: Separate subscales for hyperglycemic vs. hypoglycemic vs. fatigue vs. pain enable targeted clinical action; sum scores alone would lose this specificity.
- Recall period variability: Different versions use 2-week, 4-week, or variable recall periods; standardized version needed for comparability across studies.
- Subscale conceptual overlap: Fatigue domain shows moderate-high correlation with psychological symptom domain; distinguish which is primary (metabolic vs. affective) requires clinical judgment.
- Limited complication-specific detail: Kidney symptom subscale is brief (2-3 items); does not substitute for formal kidney disease monitoring (eGFR, albuminuria) or more detailed nephropathy-specific instruments.
- Neuropathy assessment limitations: Neuropathic pain items do not assess neuropathic phenotype (small-fiber vs. large-fiber); functional autonomic neuropathy may go undetected.
Frequently asked
Does the Diabetes Symptom Checklist replace HbA1c monitoring?
No. The checklist captures patient-experienced symptoms; HbA1c (glycated hemoglobin) provides objective glycemic control over 2-3 months. Both are complementary. A patient may have excellent HbA1c but high hypoglycemic symptom burden; another may have suboptimal HbA1c with few acute symptoms. Combined assessment enables personalized glycemic targets balancing control with quality of life.
Which subscale score elevation indicates neuropathy?
Elevated neuropathic pain subscale (typically >40-50 on 0-100 scale) suggests symptomatic neuropathy but does not diagnose it. Formal neuropathy assessment requires clinical examination, quantitative sensory testing (vibration threshold, temperature), or electromyography. Symptoms may represent other pain causes (arthritis, muscle strain); clinical correlation essential.
Can the checklist identify patients at risk for severe hypoglycemia?
Partially. High hypoglycemic symptom burden and reduced symptom awareness (low scores on symptom items despite biochemically documented hypoglycemia) raise concern for hypoglycemia unawareness, a risk factor for severe hypoglycemia. However, diagnostic confirmation requires continuous glucose monitoring or structured hypoglycemia documentation; the checklist is screening, not diagnostic.
How often should the Diabetes Symptom Checklist be administered?
Recommended frequency: baseline assessment at diabetes diagnosis or clinic enrollment, then every 3-6 months during routine follow-up, or more frequently (monthly) if evaluating treatment changes. Timing: baseline, 2-4 weeks post-intervention, and at intervals aligned with HbA1c monitoring cycles (typically 3-month intervals) for optimal responsiveness detection.
Sources
- Grootenhuis, P. A., Snoek, F. J., Heine, R. J., & Bouter, L. M. (1994). Development of a type 2 diabetes symptom checklist: A measure of symptom severity. Diabet Med, 11(3), 253-261. DOI: 10.1111/j.1464-5491.1994.tb00268.x ↗
- Snoek, F. J., Pouwer, F., Welch, G. W., & Polonsky, W. H. (1997). Diabetes-related distress in Dutch and U.S. diabetic patients: Relationship to perceived health status and depression. Diabetes Care, 20(10), 1554-1558. link ↗
How to cite this page
ScholarGate. (2026, June 3). Diabetes Symptom Checklist: Patient-Reported Symptom Dimensions. ScholarGate. https://scholargate.app/en/endocrinology/diabetes-symptom-checklist
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- AGHDAEndocrinology↔ compare
- Clarke Hypoglycemia Awareness QuestionnaireEndocrinology↔ compare
- ThyPROEndocrinology↔ compare